Cell preparation and method for producing cell preparation
The present invention provides a method for producing a cell culture for promoting angiogenesis or axon outgrowth, particularly for the treatment of a cerebrovascular disease, an ischemic cardiac disease or traumatic brain injury and spinal cord injury, which comprises culturing a cell population containing microglia and/or monocytes under conditions of low oxygen concentration and/or low sugar concentration to produce the culture, a cell preparation obtained by the method, and a method for treating a cerebrovascular disease, an ischemic cardiac disease or traumatic cerebrospinal neuropathy by using the cell preparation.
1. A method for the promotion of angiogenesis and axon outgrowth in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of autologous microglia and/or monocytes, wherein the autologous microglia and/or monocytes are obtained by;
culturing the microglia and/or monocytes in the presence of oxygen at a concentration of 1% or less and glucose at a concentration of 1.0 g/L or less for a period of 12-24 hours, thereby obtaining microglia and/or monocytes with the ability to promote angiogenesis and axon outgrowth; and
wherein the composition is administered to the subject by intravenous administration, intraperitoneal administration, intracerebral administration, intraventricular administration, intraarterial administration, or local transplantation.
2. A method for the treatment of an ischemic cerebrovascular disease, traumatic brain injury, or spinal cord injury in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of autologous microglia and/or monocytes, wherein the autologous microglia and/or monocytes are obtained by;
culturing the microglia and/or monocytes in the presence of oxygen at a concentration of 1% or less and glucose at a concentration of 1.0 g/L or less for a period of 12-24 hours, thereby obtaining microglia and/or monocytes with the ability to promote angiogenesis and axon outgrowth; and
wherein the composition is administered to the subject by intravenous administration, intraperitoneal administration, intracerebral administration, intraventricular administration, intraarterial administration, or local transplantation.
3. The method of claim 1 , wherein the composition is administered to the subject by intravenous administration.
4. The method of claim 2 , wherein the composition is administered to the subject by intravenous administration.
5. The method of claim 1 , wherein the monocytes are collected from peripheral blood.
6. The method of claim 1 , wherein the monocytes are isolated from a fraction comprising mononuclear cells collected from peripheral blood.
7. The method of claim 1 , wherein the low oxygen concentration is an oxygen concentration of 0.1 to 0.4%.
8. The method of claim 1 , wherein the culture period is about 18 hr.
9. The method of claim 2 , wherein the monocytes are collected from peripheral blood.
10. The method of claim 2 , wherein the monocytes are isolated from a fraction comprising mononuclear cells collected from peripheral blood.
11. The method of claim 2 , wherein the low oxygen concentration is an oxygen concentration of 0.1 to 0.4%.
12. The method of claim 2 , wherein the culture period is about 18 hr.